Modine Stock Hits New 52-Week Low (MOD)

NEW YORK ( TheStreet) -- Modine Manufacturing Company (NYSE: MOD) hit a new 52-week low Monday as it is currently trading at $8.82, below its previous 52-week low of $8.85 with 102,841 shares traded as of 1:19 p.m. ET. Average volume has been 333,400 shares over the past 30 days.

Modine has a market cap of $448.8 million and is part of the consumer goods sector and automotive industry. Shares are down 41.5% year to date as of the close of trading on Friday.

Modine Manufacturing Company engages in the development, manufacture, and marketing of heat exchangers and systems for use in on-highway and off-highway original equipment manufacturer (OEM) vehicular applications, and to various building, industrial, refrigeration, and fuel cell markets. The company has a P/E ratio of 26, below the average automotive industry P/E ratio of 26.8 and above the S&P 500 P/E ratio of 17.7.
  • Practice your MOD trading strategies and win cash in our stock game.

TheStreet Ratings rates Modine as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including poor profit margins and a generally disappointing performance in the stock itself. You can view the full Modine Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus